SELLAS Life Sciences Group, Inc. Common Stock
SLS
$10.09
-6.88%
SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing novel immunotherapies and targeted small molecule inhibitors for cancer, with lead candidates including galinpepimut-S (GPS) targeting WT1 and GFH009, a CDK9 inhibitor. As a niche player in oncology, it focuses on addressing unmet needs in hematologic malignancies and solid tumors. The current investor narrative centers on the stock's explosive price surge driven by clinical data milestones and pipeline progress, though debates persist around the sustainability of valuation given the lack of approved products and ongoing cash burn.…
SLS
SELLAS Life Sciences Group, Inc. Common Stock
$10.09
SLS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on SELLAS Life Sciences Group, Inc. Common Stock's 12-month outlook, with a consensus price target around $27.50 and implied upside of +172.6% versus the current price.
Average Target
$27.50
0 analysts
Implied Upside
+172.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$25 - $30
Analyst target range
Only 2 analysts cover SELLAS, with an average target price of $27.50, implying 143% upside from the current price of $11.32. The consensus recommendation is not provided (listed as 'none'), but the institutional ratings show repeated Buy/Overweight ratings from Maxim Group, Cantor Fitzgerald, and Alliance Global Partners, indicating a bullish lean. The target range is $25.00 (low) to $30.00 (high). The high target of $30.00 assumes successful clinical development and potential commercialization, while the low target of $25.00 still implies significant upside. The narrow spread ($5) relative to the average suggests relatively high conviction among the few analysts. However, limited coverage (2 analysts) means the stock may be underfollowed, leading to higher volatility and less efficient price discovery. The estimated EPS for the next fiscal year is $2.55, which seems optimistic given current losses, and estimated revenue of $630 million implies a major inflection point, likely from product sales if approved.
Bulls vs Bears: SLS Investment Factors
SELLAS Life Sciences presents a high-risk, high-reward profile typical of pre-commercial biotech. The bull case rests on the massive 143% upside to analyst targets, explosive price momentum, and a strong cash position with no debt. However, the bear case highlights zero revenue, widening losses, reliance on equity financing, and limited analyst coverage. The single most important tension is whether the pipeline (GPS and GFH009) will achieve clinical and regulatory success; positive data could propel the stock toward $30, while any setback could trigger a sharp decline toward the 52-week low of $1.39. Currently, the bull case has stronger evidence given the sustained momentum and analyst conviction, but the risk of failure remains substantial.
Bullish
- Massive Analyst Upside Potential: The average analyst target price is $27.50, implying 143% upside from the current price of $11.32. The high target of $30.00 suggests even greater potential, reflecting strong conviction in the pipeline's value.
- Explosive Price Momentum: The stock has surged 518.6% over the past year, massively outperforming the S&P 500's 16.5% gain. The 3-month change of +153.8% and 1-month change of +23.4% indicate accelerating momentum driven by clinical catalysts.
- Strong Liquidity Position: Cash and equivalents stood at $107.2 million as of Q1 2026, up from $71.9 million at year-end 2025, providing a runway for clinical trials. The current ratio of 10.7 indicates ample short-term liquidity to fund operations.
- Minimal Debt Burden: With a debt-to-equity ratio of just 0.014, the company has virtually no debt. This low leverage reduces financial risk and provides flexibility to raise additional capital if needed.
Bearish
- Zero Revenue and Widening Losses: The company has no approved products, generating $0 in revenue for Q1 2026. Net loss widened to -$8.4 million from -$5.8 million a year ago, with operating expenses rising 52% to $9.3 million as R&D spending increased.
- Dependence on External Financing: Free cash flow was -$8.8 million in Q1 2026 and -$28.2 million over the trailing twelve months. The company relies on equity issuances to fund operations, which dilutes existing shareholders.
- Limited Analyst Coverage: Only 2 analysts cover the stock, leading to less efficient price discovery and higher volatility. The narrow coverage means the market may be slow to react to news or overreact to data.
- Extreme Valuation Risk: With a price-to-book ratio of 5.80 and negative earnings, the stock trades at a premium to tangible book value. The forward PE of -90.56 reflects expectations of continued losses, leaving no room for error.
SLS Technical Analysis
The stock is in a powerful sustained uptrend, with a 1-year price change of +518.6%, massively outperforming the S&P 500's +16.5%. Currently trading at $11.32, it sits at 71.3% of its 52-week range ($1.39–$15.88), indicating strong momentum but not yet at overbought extremes near the high. The price has rallied from a low of $1.39 to a high of $15.88, reflecting a 10.4x increase over the period. Short-term momentum is accelerating, with a 1-month change of +23.4% and a 3-month change of +153.8%, both far exceeding the S&P 500's 0.8% and 3.5% respectively. This divergence from the broader market signals strong stock-specific catalysts, likely clinical trial readouts or partnership news. The 1-month relative strength of +22.7% confirms continued buying pressure. The 52-week high of $15.88 acts as immediate resistance; a breakout above this level would signal further upside potential toward analyst targets. Support lies at the 52-week low of $1.39, though the stock is far above that. With a beta of 2.425, the stock is 142.5% more volatile than the market, implying significant price swings and requiring careful risk management.
Beta
2.42
2.42x market volatility
Max Drawdown
-36.5%
Largest decline past year
52-Week Range
$1-$16
Price range past year
Annual Return
+466.9%
Cumulative gain past year
| Period | SLS Return | S&P 500 |
|---|---|---|
| 1m | -18.6% | +1.6% |
| 3m | +116.1% | +4.1% |
| 6m | +159.4% | +6.8% |
| 1y | +466.9% | +16.3% |
| ytd | +132.0% | +8.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SLS Fundamental Analysis
SELLAS has zero revenue, as it is a pre-commercial biotechnology company. The most recent quarterly revenue (Q1 2026) was $0, consistent with all prior quarters. The company's growth trajectory is entirely dependent on pipeline advancement and potential regulatory approvals, not current sales. Net income for Q1 2026 was -$8.4 million, a loss per share of -$0.0487, compared to -$5.8 million in Q1 2025, indicating widening losses. The company is unprofitable with no gross margin (gross profit $0). Operating expenses were $9.3 million in Q1 2026, up from $6.1 million in Q1 2025, driven by increased R&D spending ($5.1 million vs $3.2 million). The net loss is expanding as the company invests in clinical trials. Balance sheet shows cash of $107.2 million as of Q1 2026, up from $71.9 million at year-end 2025, thanks to equity financing. Debt is minimal (debt-to-equity 0.014), and the current ratio is 10.7, indicating strong liquidity. However, free cash flow was -$8.8 million in Q1 2026 and -$28.2 million over the trailing twelve months, meaning the company relies on external capital (equity issuances) to fund operations. ROE is -37.9%, reflecting persistent losses.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-28165000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SLS Overvalued?
Since net income is negative, the trailing PE ratio is not meaningful (-15.08). The primary valuation metric is the price-to-sales (PS) ratio, but with zero revenue, PS is undefined. Instead, we use the price-to-book (PB) ratio of 5.80, which compares market cap to book value. The forward PE is -90.56, indicating analysts expect continued losses. The negative PE values reflect the lack of profitability. Compared to the biotechnology industry average PB (typically around 4-6x), SELLAS trades at a slight premium, but this is common for companies with promising pipelines. The PB of 5.80 is below the historical high of 26.38 seen in Q1 2022, but above the low of -4.09 (negative book value) in Q4 2023. The current PB is near the middle of its historical range, suggesting the market is pricing in moderate expectations for future value creation. The EV/EBITDA of -12.67 is negative due to negative EBITDA, confirming the company is not yet generating positive operating earnings.
PE
-15.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-12.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The company has zero revenue and is burning cash at an accelerating rate, with Q1 2026 operating expenses of $9.3 million up from $6.1 million a year ago. Free cash flow was -$28.2 million over the trailing twelve months, and the net loss widened to -$8.4 million in Q1 2026. While the current cash balance of $107.2 million provides a runway, the company will likely need to raise additional capital through equity offerings, diluting shareholders. The negative ROE of -37.9% and ROA of -25.5% underscore the lack of profitability and inefficient capital use.
Market & Competitive Risks: The stock's beta of 2.425 makes it 142.5% more volatile than the market, exposing it to macro sell-offs. The price-to-book ratio of 5.80 is above the industry average, implying a premium that could compress if pipeline progress stalls. With only 2 analysts covering the stock, information asymmetry is high, and the stock may be prone to sharp moves on news. The short ratio of 6.31 indicates elevated short interest, suggesting many investors are betting against the stock, which could amplify downside if negative data emerges.
Worst-Case Scenario: If a key clinical trial fails or regulatory hurdles arise, the stock could collapse to its 52-week low of $1.39, representing a -87.7% decline from the current price of $11.32. This scenario would likely involve the company exhausting its cash runway without achieving milestones, forcing dilutive financing or bankruptcy. The historical max drawdown of -36.53% (likely from a recent peak) shows the stock's capacity for sharp reversals.